VRCA

Verrica Pharmaceuticals Inc. VRCA

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,499 of 2,925

Why it scores 30Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$5.86M

Quarter to Jun 30

Net income

$-13.15M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$28.78M total
Caligan Partners LP
$5.65M0.0%
CANNELL CAPITAL LLC
$4.80M+14.4%
Affinity Asset Advisors, LLC
$4.33M0.0%
Velan Capital Investment Management LP
$2.89M0.0%
ARMISTICE CAPITAL, LLC
$2.61M-17.7%
BOOTHBAY FUND MANAGEMENT, LLC
$1.72M0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$1.71M+48.0%
Mariner, LLC
$1.27M+744.3%
GEODE CAPITAL MANAGEMENT, LLC
$845.7K-0.5%
BlackRock, Inc.
$455.0K+92.8%
VANGUARD FIDUCIARY TRUST CO
$429.5K+7.8%
TWO SIGMA INVESTMENTS, LP
$249.8K-19.4%
Stonepine Capital Management, LLC
$241.5K-11.3%
STATE STREET CORP
$177.0K0.0%
NORTHERN TRUST CORP
$165.2K-14.5%
DAFNA Capital Management LLC
$145.3K-84.5%
JANE STREET GROUP, LLC
$144.8K-51.9%
Verdad Advisers, LP
$141.2K+90.7%
RENAISSANCE TECHNOLOGIES LLC
$133.2K-32.7%
Legacy Trust
$101.5K-3.8%
FIFTH THIRD BANCORP
$85.7KNew
DIMENSIONAL FUND ADVISORS LP
$85.0KNew
XTX Topco Ltd
$84.0KNew
TWO SIGMA SECURITIES, LLC
$79.8KNew
HRT FINANCIAL LP
$79.0KNew
See all 44 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/VRCA

Earnings Per Share

13fpro.ai/company/VRCA

Loading ratio trend…

VRCA key financials by period

Reported revenue, net income and operating margin by fiscal year, from Verrica Pharmaceuticals Inc.'s annual filings on SEC EDGAR.

Verrica Pharmaceuticals Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$35.6M$-17.9M-34.3%
FY 2024$7.6M$-76.6M—
FY 2023$5.1M$-67.0M—
FY 2022$9.0M$-24.5M—
FY 2021$12.0M$-35.1M—
Source: VRCA filings on SEC EDGAR →

Companies similar to VRCA

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

VRCA insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Verrica Pharmaceuticals Inc. (VRCA): stock profile, AI score and financials

Verrica Pharmaceuticals Inc. (VRCA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VRCA at 29.6/100 on a composite quality score built from its SEC filings, placing it at rank #2,499 of 2,925 stocks — the bottom half of the AI-ranked universe. VRCA scores in the top quartile across revenue growth (96.0). Areas of concern include balance sheet strength (1.7) and revenue scale (5.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 16.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Verrica Pharmaceuticals Inc. reports quarterly revenue of $5.9M, net income of $-13.2M. Top institutional holders of VRCA by reported 13-F value include Caligan Partners, CANNELL CAPITAL, Affinity Asset Advisors, based on the most recent SEC filings. VRCA trades on the Nasdaq exchange and files with the SEC under CIK 1660334. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VRCA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Verrica Pharmaceuticals Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1660334 →